Antibiotics Could Get Double Exclusivity Under House Bill; FDA Makes Its Own Moves

Five years of additional exclusivity, priority review and fast-track status are the carrots offered in legislation introduced by Rep. Phil Gingrey, R.-Ga., June 15 to entice drug makers to develop antimicrobials for drug-resistant pathogens.